Tech Journal of Colorado
SEE OTHER BRANDS

Get your fresh news on science and technology in Colorado

Tech Journal of Colorado: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.

Press releases published on May 12, 2025

XRP News: XRP Hits $2.60, Vaultro Finance Presale Heats Up as XRP Investors Look for the Next Big DeFi Win - Join $VLT Presale

XRP News: XRP Hits $2.60, Vaultro Finance Presale Heats Up as XRP Investors Look for the Next Big DeFi Win - Join $VLT Presale

SINGAPORE, May 12, 2025 (GLOBE NEWSWIRE) -- With XRP officially crossing the $2.50 mark, bullish sentiment has returned in full force across the XRP Ledger ecosystem. And at the center of this renewed energy is Vaultro Finance, the first decentralized …

 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b …

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in …

Microchip Technology to Present at the J.P. Morgan 53rd Annual Global Technology, Media, and Communications Conference

Microchip Technology to Present at the J.P. Morgan 53rd Annual Global Technology, Media, and Communications Conference

CHANDLER, Ariz., May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the J.P. Morgan 53rd Annual …

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European …

Rigetti Computing Reports First Quarter 2025 Financial Results

Rigetti Computing Reports First Quarter 2025 Financial Results

BERKELEY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the first quarter ended March 31, 2025. …

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025 Cash, …

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise …

GigaCloud Technology Inc Announces First Quarter Ended March 31, 2025 Financial Results

GigaCloud Technology Inc Announces First Quarter Ended March 31, 2025 Financial Results

EL MONTE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced financial results for the first …

Akoya Biosciences Reports First Quarter 2025 Financial Results

Akoya Biosciences Reports First Quarter 2025 Financial Results

MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. “Akoya remained focused on operational …

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 …

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

Q1 revenue of $21.9 million, increasing 11% year-over-year Q1 gross profit increased 9% year-over-year to $13.3 million Increases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK

LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets …

Rapid7 Announces First Quarter 2025 Financial Results

Rapid7 Announces First Quarter 2025 Financial Results

Annualized recurring revenue (“ARR”) of $837 million, an increase of 4% year-over-year Total revenue of $210 million, up 3% year-over-year; Product subscriptions revenue of $204 million, up 4% year-over-year GAAP operating loss of $0.1 million; Non-GAAP …

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a …

Lantronix Appoints Sailesh Chittipeddi to Its Board of Directors

Lantronix Appoints Sailesh Chittipeddi to Its Board of Directors

IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced that Sailesh Chittipeddi, Ph.D., has joined the Lantronix Board of …

Phunware Reports First Quarter 2025 Financial Results

Phunware Reports First Quarter 2025 Financial Results

New Customer Launches Drive 40% Revenue Growth for Software Subscriptions and Services Strong Balance Sheet of $109.7 Million Powering R…

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152, …

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2  …

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service